- Advertisement -

- Advertisement -

MiNK Therapeutics to Participate at Upcoming B. Riley

43

- Advertisement -

- Advertisement -

NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) — MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 27th, 2022, at 12:00 pm ET.

Access to the live presentation is available at https://www.webcaster4.com/Webcast/Page/2828/44096

A replay will be available after the call on the Events and Presentations page of the MiNK website at https://investor.minktherapeutics.com/events-and-presentations

About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/.

Contact
MiNK Therapeutics 
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com 

 

- Advertisement -

Also Read This

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More